Inspire Medical Systems R&D Spending Growth & History (INSP)
Inspire Medical Systems's r&d spending was $103.2M for fiscal 2025.
View full Inspire Medical Systems company overviewInspire Medical Systems annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $103.2M | −$11.0M | −9.61% |
| 2024 | 2024-12-31 | $114.1M | −$2.4M | −2.07% |
| 2023 | 2023-12-31 | $116.5M | $47.9M | +69.77% |
| 2022 | 2022-12-31 | $68.6M | $31.3M | +83.79% |
| 2021 | 2021-12-31 | $37.4M | $11.3M | +43.15% |
| 2020 | 2020-12-31 | $26.1M | $13.3M | +103.22% |
| 2019 | 2019-12-31 | $12.8M | $5.5M | +73.78% |
| 2018 | 2018-12-31 | $7.4M | $1.2M | +19.28% |
| 2017 | 2017-12-31 | $6.2M | — | — |
Inspire Medical Systems quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $24.7M | −$1.5M | −5.77% |
| Q1 2026 | 2026-03-31 | $25.8M | −$2.0M | −7.11% |
| Q4 2025 | 2025-12-31 | $24.9M | −$5.4M | −17.78% |
| Q3 2025 | 2025-09-30 | $24.2M | −$1.9M | −7.18% |
| Q2 2025 | 2025-06-30 | $26.2M | −$2.6M | −9.18% |
| Q1 2025 | 2025-03-31 | $27.8M | −$1.0M | −3.63% |
| Q4 2024 | 2024-12-31 | $30.3M | −$716,000 | −2.31% |
| Q3 2024 | 2024-09-30 | $26.1M | −$3.1M | −10.50% |
| Q2 2024 | 2024-06-30 | $28.9M | −$2.0M | −6.37% |
| Q1 2024 | 2024-03-31 | $28.9M | $3.3M | +13.05% |
| Q4 2023 | 2023-12-31 | $31.1M | $9.8M | +46.14% |
| Q3 2023 | 2023-09-30 | $29.1M | $8.2M | +38.83% |
| Q2 2023 | 2023-06-30 | $30.8M | $16.3M | +112.06% |
| Q1 2023 | 2023-03-31 | $25.5M | $13.6M | +114.99% |
| Q4 2022 | 2022-12-31 | $21.2M | $11.0M | +106.41% |
| Q3 2022 | 2022-09-30 | $21.0M | $11.4M | +118.36% |
| Q2 2022 | 2022-06-30 | $14.5M | $5.2M | +56.48% |
| Q1 2022 | 2022-03-31 | $11.9M | $3.7M | +45.57% |
| Q4 2021 | 2021-12-31 | $10.3M | $3.0M | +41.30% |
| Q3 2021 | 2021-09-30 | $9.6M | $2.3M | +31.57% |
| Q2 2021 | 2021-06-30 | $9.3M | $3.2M | +53.22% |
| Q1 2021 | 2021-03-31 | $8.2M | $2.7M | +49.94% |
| Q4 2020 | 2020-12-31 | $7.3M | $3.5M | +93.39% |
| Q3 2020 | 2020-09-30 | $7.3M | $3.7M | +101.68% |
| Q2 2020 | 2020-06-30 | $6.1M | $3.2M | +113.00% |
| Q1 2020 | 2020-03-31 | $5.4M | $2.8M | +108.91% |
| Q4 2019 | 2019-12-31 | $3.8M | $1.6M | +75.05% |
| Q3 2019 | 2019-09-30 | $3.6M | $1.9M | +104.57% |
| Q2 2019 | 2019-06-30 | $2.8M | $1.1M | +64.03% |
| Q1 2019 | 2019-03-31 | $2.6M | $873,000 | +50.46% |
| Q4 2018 | 2018-12-31 | $2.2M | $470,000 | +27.94% |
| Q3 2018 | 2018-09-30 | $1.8M | $595,000 | +50.60% |
| Q2 2018 | 2018-06-30 | $1.7M | −$8,000 | −0.46% |
| Q1 2018 | 2018-03-31 | $1.7M | $137,000 | +8.60% |
| Q4 2017 | 2017-12-31 | $1.7M | — | — |
| Q3 2017 | 2017-09-30 | $1.2M | — | — |
| Q2 2017 | 2017-06-30 | $1.7M | — | — |
| Q1 2017 | 2017-03-31 | $1.6M | — | — |
Inspire Medical Systems r&d spending trends
Over the last five fiscal years, Inspire Medical Systems's r&d spending increased from $26.1M to $103.2M, a change of $77.1M. The latest reported quarter, Q2 2026, shows $24.7M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inspire Medical Systems source filings ↗